For the first time in the history of Medicare Part D, generic drugs make up a bigger share of non-preferred formulary tiers where they cost more, which discourages consumers from choosing generics, according to a new analysis from Avalere. In 2017, a Part D policy took effect that makes it easier for insurers to favor brand drugs over generics on formularies. Prior to that, nonpreferred drug tiers had to include more generics than brands. The new policy made it easier...